Singular Genomics Systems, Inc. provided unaudited revenue guidance for the fourth quarter of 2023. For the quarter, the company revenue is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765,000 during the fourth quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.7 USD | -5.38% | -12.12% | -36.97% |
06-24 | Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm... | |
06-21 | Singular Genomics Systems to Implement 1-For-30 Reverse Stock Split | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.97% | 645M | |
+38.36% | 52.73B | |
+38.68% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- OMIC Stock
- News Singular Genomics Systems, Inc.
- Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023